292 related articles for article (PubMed ID: 31682552)
1. Reducing risk in thiopurine therapy.
Marinaki AM; Arenas-Hernandez M
Xenobiotica; 2020 Jan; 50(1):101-109. PubMed ID: 31682552
[TBL] [Abstract][Full Text] [Related]
2. Implementation of TPMT testing.
Lennard L
Br J Clin Pharmacol; 2014 Apr; 77(4):704-14. PubMed ID: 23962279
[TBL] [Abstract][Full Text] [Related]
3. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
4. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.
Asadov C; Aliyeva G; Mustafayeva K
Cardiovasc Hematol Agents Med Chem; 2017 Nov; 15(1):23-30. PubMed ID: 28552060
[TBL] [Abstract][Full Text] [Related]
6. Metabolite monitoring to guide thiopurine therapy in systemic autoimmune diseases.
Chapdelaine A; Mansour AM; Troyanov Y; Williamson DR; Doré M
Clin Rheumatol; 2017 Jun; 36(6):1341-1348. PubMed ID: 28130685
[TBL] [Abstract][Full Text] [Related]
7. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.
Lennard L; Van Loon JA; Lilleyman JS; Weinshilboum RM
Clin Pharmacol Ther; 1987 Jan; 41(1):18-25. PubMed ID: 3467886
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
9. Update on thiopurine pharmacogenetics in inflammatory bowel disease.
Roberts RL; Barclay ML
Pharmacogenomics; 2015 Jul; 16(8):891-903. PubMed ID: 26067482
[TBL] [Abstract][Full Text] [Related]
10. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.
van Gennep S; Konté K; Meijer B; Heymans MW; D'Haens GR; Löwenberg M; de Boer NKH
Aliment Pharmacol Ther; 2019 Sep; 50(5):484-506. PubMed ID: 31342537
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
[TBL] [Abstract][Full Text] [Related]
12. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
[TBL] [Abstract][Full Text] [Related]
13. Analytic aspects of monitoring therapy with thiopurine medications.
Armstrong VW; Shipkova M; von Ahsen N; Oellerich M
Ther Drug Monit; 2004 Apr; 26(2):220-6. PubMed ID: 15228169
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
Teml A; Schaeffeler E; Herrlinger KR; Klotz U; Schwab M
Clin Pharmacokinet; 2007; 46(3):187-208. PubMed ID: 17328579
[TBL] [Abstract][Full Text] [Related]
15. Severe pancytopenia and aspergillosis caused by thioguanine in a thiopurine S-methyltransferase deficient patient: a case report.
de Hoogd S; Wong DR; de Vries DR; Harmsze AM
Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1592-1596. PubMed ID: 31464791
[TBL] [Abstract][Full Text] [Related]
16. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
17. Establishment of thiopurine S-methyltransferase gene knockdown in jurkat T-lymphocytes: an in vitro model of TPMT polymorphism.
Misdaq M; Andag R; Oellerich M; Asif AR; von Ahsen N
Ther Drug Monit; 2012 Oct; 34(5):584-92. PubMed ID: 22972540
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
19. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
20. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
